June 2022
Volume 63, Issue 7
Open Access
ARVO Annual Meeting Abstract  |   June 2022
A CRISPR-based inducible system for VEGF repression for AMD
Author Affiliations & Notes
  • Shusheng Wang
    Cell and Molecular biology, Tulane University School of Science and Engineering, New Orleans, Louisiana, United States
    Ophthalmology, Tulane University School of Medicine, New Orleans, Louisiana, United States
  • Yao Tong
    Cell and Molecular biology, Tulane University School of Science and Engineering, New Orleans, Louisiana, United States
  • Yinga Wu
    Cell and Molecular biology, Tulane University School of Science and Engineering, New Orleans, Louisiana, United States
  • Jing Ma
    Cell and Molecular biology, Tulane University School of Science and Engineering, New Orleans, Louisiana, United States
  • Zunyi Zhang
    Cell and Molecular biology, Tulane University School of Science and Engineering, New Orleans, Louisiana, United States
  • Footnotes
    Commercial Relationships   Shusheng Wang Tulane University, Code P (Patent); Yao Tong None; Yinga Wu None; Jing Ma None; Zunyi Zhang None
  • Footnotes
    Support  BrightFocus Foundation Grant in AMD
Investigative Ophthalmology & Visual Science June 2022, Vol.63, 1951 – F0369. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Shusheng Wang, Yao Tong, Yinga Wu, Jing Ma, Zunyi Zhang; A CRISPR-based inducible system for VEGF repression for AMD. Invest. Ophthalmol. Vis. Sci. 2022;63(7):1951 – F0369.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose : Age-related macular degeneration (AMD) is the primary cause of irreversible blindness in the elderly. The current paradigm for wet AMD treatment is monthly intravitreal injection of anti-VEGF antibodies, which poses a significant economic burden to the patients. Continuous blocking of VEGF may have adverse effect in choroid capillaries and the ciliary body. We propose a gene therapy approach to drive inducible and reversible VEGF repression using a CRISPR-based system, which could avoid repetitive intravitreal injection while achieving controllable VEGF repression.

Methods : ARPE-19 and mouse RPE cell lines were engineered to express Cas9-Krab reversibly as controlled by doxycycline (Dox), which was confirmed by Western blot analysis and immunostaining. A series of guide RNA pairs targeting human (mouse) VEGF promoter were used in screening to identify guide RNAs that can repress VEGF expression. constitutively expressed. Real-time PCR and ELISA were employed to quantify the VEGF expression before and after Dox treatment in the system. Laser injury model is being used to evaluate the efficacy of the approach in vivo.

Results : Induction and dosage-response of Cas9-Krab expression were confirmed by Western blot analysis and immunostaining. In addition, Cas9-Krab can be reinduced in the same cells within 12 hours 7 days after the first induction. Guide RNAs have been screened to target VEGF promoter RPE cells. Up to 90% reduction of VEGF mRNA and protein expression has been achieved in the system.

Conclusions : We have established a CRISPR-based reversible VEGF repression system, which could be used to treating retinal diseases including AMD and diabetic retinopathy. (This research has been supported by a grant from BrightFocus Foundation)

This abstract was presented at the 2022 ARVO Annual Meeting, held in Denver, CO, May 1-4, 2022, and virtually.

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×